Therefore, our results should not be interpreted to suggest that FLT3 inhibitors would be preferentially active in pediatric AML patients with KMT2A/MLL rearrangements, as many cases without KMT2A/MLL rearrangements whose leukemia cells are FLT3-ITD+ may also benefit from FLT3 inhibitors. The gene discussed is KMT2A; the disease is acute myeloid leukemia.